| human | Q5 |
| P6178 | Dimensions author ID | 01221137662.59 |
| P269 | IdRef ID | 111519055 |
| P496 | ORCID iD | 0000-0001-7509-3510 |
| P214 | VIAF ID | 211258475 |
| P7859 | WorldCat Identities ID (superseded) | viaf-211258475 |
| P69 | educated at | Aristotle University of Thessaloniki | Q667568 |
| Paris 12 University | Q980688 | ||
| University of Paris-Sud | Q1480643 | ||
| P108 | employer | National Centre of Scientific Research "DEMOKRITOS" | Q3559155 |
| Beth Israel Deaconess Medical Center | Q4897536 | ||
| NYU Langone Medical Center | Q6956114 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q35871567 | 19p13.1 is a triple-negative-specific breast cancer susceptibility locus |
| Q92224274 | A Mendelian randomization analysis of circulating lipid traits and breast cancer risk |
| Q37602441 | A Paternally Inherited BRCA1 Mutation Associated with an Unusual Aggressive Clinical Phenotype |
| Q64897673 | A Patient Affected with Serous Ovarian/Peritoneal Carcinoma Carrying the FANCM Mutation. |
| Q59355837 | A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk |
| Q44009195 | A change in the last base of BRCA1 exon 23, 5586G-->A, results in abnormal RNA splicing |
| Q35755874 | A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer |
| Q43208393 | A distinct mutation on the alternative splice site of APC exon 9 results in attenuated familial adenomatous polyposis phenotype |
| Q37619303 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium |
| Q35089479 | A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population |
| Q42517629 | A newly detected mutation of the RET protooncogene in exon 8 as a cause of multiple endocrine neoplasia type 2A. |
| Q36557055 | A point mutation in the extracellular domain activates LET-23, the Caenorhabditis elegans epidermal growth factor receptor homolog. |
| Q57728280 | A rareRETgene exon 8 mutation is found in two Greek kindreds with familial medullary thyroid carcinoma: implications for screening |
| Q53364054 | Absence of association with cancer risk and low frequency of alterations at a p53 responsive PIG3 gene polymorphism in breast and lung carcinomas. |
| Q53403786 | Absence of mutations in the functional domains of the human MDM2 oncogene in non-small cell lung carcinomas. |
| Q61948755 | Abstract 3266: Expression quantitative trait locus analysis of triple negative breast cancer |
| Q36882665 | An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers |
| Q43591072 | An in-frame exon-skipping MUTYH mutation is associated with early-onset colorectal cancer |
| Q35618307 | An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers |
| Q91271723 | Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness |
| Q99609984 | Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer |
| Q35957703 | Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer |
| Q57728283 | Atypical Medullary Breast Carcinoma in a Family Carrying the 5382insC BRCA-1 Mutation |
| Q57728286 | BRCA1 and BRCA2 genes mutation analysis in patients with a family history of breast and ovarian cancer |
| Q89542103 | BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects |
| Q46945553 | BRCA1 mutation analysis in breast and ovarian cancer families from Greece. |
| Q44909070 | BRCA1 mutation analysis in breast/ovarian cancer families from Greece |
| Q62937872 | BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations |
| Q28213349 | BRCA2 gene mutations in Greek patients with familial breast cancer |
| Q62937861 | Breast cancer risk inBRCA1 andBRCA2 mutation carriers and polyglutamine repeat length in theAIB1 gene |
| Q57305977 | Breast-Cancer Risk in Families With Mutations in PALB2 |
| Q34148873 | Breast-cancer risk in families with mutations in PALB2 |
| Q51037523 | CHEK2 c.1100delC allele is rarely identified in Greek breast cancer cases. |
| Q112840876 | CanVaS: Documenting the genetic variation spectrum of Greek cancer patients |
| Q114657791 | Cancer Risks Associated With and Pathogenic Variants |
| Q54108246 | Characterization and prevalence of two novel CHEK2 large deletions in Greek breast cancer patients. |
| Q24796063 | Characterization of a novel large deletion and single point mutations in the BRCA1 gene in a Greek cohort of families with suspected hereditary breast cancer |
| Q57499928 | Collaborative genomics for human health and cooperation in the Mediterranean region |
| Q62937866 | Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers |
| Q35891162 | Common breast cancer susceptibility loci are associated with triple-negative breast cancer |
| Q34379032 | Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium |
| Q37269654 | Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases |
| Q90967024 | Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece |
| Q46600471 | Correction: Prevalence of BRCA1 Mutations in Familial andSporadic Greek Ovarian Cancer Cases |
| Q101216461 | Cross-cancer genome-wide association study of endometrial cancer and epithelial ovarian cancer identifies genetic risk regions associated with risk of both cancers |
| Q62937857 | Culture of primary epithelial adenoma cells from familial adenomatous polyposis patients |
| Q21144874 | DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q52802357 | Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy among patients with idiopathic and functional hypothalamic amenorrhea: a systematic review of the literature and a meta-analysis. |
| Q40489875 | Epidemiological and clinicopathological characteristics of BRCA-positive and BRCA-negative breast cancer patients in Greece |
| Q37481884 | Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). |
| Q54520898 | Evaluation of dHPLC in mutation screening of the APC gene in a Greek FAP cohort. |
| Q35064451 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation |
| Q91687896 | Extending the clinical phenotype associated with biallelic NTHL1 germline mutations |
| Q37594336 | FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium |
| Q36111237 | Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus |
| Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
| Q61230414 | Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes |
| Q92480972 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes |
| Q34903062 | Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. |
| Q38341457 | Fully integrated monolithic optoelectronic transducer for real-time protein and DNA detection: the NEMOSLAB approach |
| Q92239198 | Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system |
| Q36124728 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus |
| Q36742577 | Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers |
| Q57390836 | G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history |
| Q33589487 | Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes |
| Q62583319 | Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk |
| Q54520893 | Genetic alterations of the APC gene in familial adenomatous polyposis patients of the hellenic group for the study of colorectal cancer. |
| Q47195956 | Genetic analysis and clinical description of Greek patients with Peutz-Jeghers syndrome: Creation of a National Registry. |
| Q62937870 | Genetic counseling of medullary breast cancer patients |
| Q54214613 | Genetic evaluation based on family history and Her2 status correctly identifies TP53 mutations in very early onset breast cancer cases. |
| Q35179897 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study |
| Q34378972 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade |
| Q28388497 | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types |
| Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
| Q63681757 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer |
| Q29417100 | Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer |
| Q95329367 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses |
| Q27008356 | Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk |
| Q34141317 | Germ line BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed |
| Q47553036 | Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer |
| Q48255561 | Glutathione-mediated metabolism of technetium-99m SNS/S mixed ligand complexes: a proposed mechanism of brain retention |
| Q57728295 | Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients |
| Q57728262 | Growth index is independent of microvessel density in non–small-cell lung carcinomas |
| Q57728244 | Haplotype analysis of two recurrent genomic rearrangements in the BRCA1 gene suggests they are founder mutations for the Greek population |
| Q40674850 | Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation |
| Q57471595 | Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study |
| Q36276540 | Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization |
| Q57728252 | Hereditary cancer syndromes |
| Q51786624 | High prevalence of BRCA1 founder mutations in Greek breast/ovarian families. |
| Q62937883 | Human erythrocyte band 3 polymorphism (band 3 Memphis): characterization of the structural modification (Lys 56----Glu) by protein chemistry methods |
| Q35102646 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk |
| Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
| Q36086247 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus |
| Q46103372 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer |
| Q57728299 | Identifying and testing for hereditary susceptibility to breast/ovarian cancer in Serbia: Where are we now? |
| Q38300235 | Improved DNA microarray detection sensitivity through immobilization of preformed in solution streptavidin/biotinylated oligonucleotide conjugates. |
| Q34996647 | Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer |
| Q35104068 | Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer |
| Q53171003 | International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. |
| Q57728257 | Lack of association between RNASEL Arg462Gln variant and the risk of breast cancer |
| Q57191573 | Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair |
| Q28267893 | Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair |
| Q92860654 | Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers |
| Q34497352 | MicroRNA related polymorphisms and breast cancer risk |
| Q24321917 | Molecular cloning, expression, and chromosomal localization of two isoforms of the AE3 anion exchanger from human heart |
| Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
| Q49024646 | Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations. |
| Q47101296 | Mutational analysis of TSC1 and TSC2 genes in Tuberous Sclerosis Complex patients from Greece. |
| Q30986219 | Mutational spectrum of APC and genotype-phenotype correlations in Greek FAP patients |
| Q54566839 | Novel genomic rearrangements in the BRCA1 gene detected in Greek breast/ovarian cancer patients. |
| Q62937876 | Novel mutations of the APC gene in familial adenomatous polyposis in Greek patients |
| Q34705352 | On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations |
| Q91840312 | One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene |
| Q92023416 | PALB2 c.2257C>T truncating variant is a Greek founder and is associated with high breast cancer risk |
| Q28584533 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS |
| Q92930759 | Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections |
| Q62937887 | Phosphorylation sites in human erythrocyte band 3 protein |
| Q100541159 | Pitfalls in variant annotation for hereditary cancer diagnostics: The example of Illumina® VariantStudio® |
| Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
| Q97524107 | Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants |
| Q36066735 | Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q50485704 | Prelingual nonsyndromic hearing loss in Greece. Molecular and clinical findings. |
| Q92853435 | Prevalence and founder effect of the BRCA1 p.(Val1833Met) variant in the Greek population, with further evidence for pathogenicity and risk modification |
| Q54522260 | Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. |
| Q34639149 | Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases |
| Q50486950 | Prevalence of GJB2 mutations in prelingual deafness in the Greek population. |
| Q62937890 | Primary structure of the cytoplasmic domain of human erythrocyte protein band 3. Comparison with its sequence in the mouse |
| Q62937880 | Proteolytic Cleavage Sites of Native AE2 Anion Exchanger in Gastric Mucosal Membranes† |
| Q55508030 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. |
| Q90242034 | Publisher Correction: Shared heritability and functional enrichment across six solid cancers |
| Q36009422 | RAD51B in Familial Breast Cancer |
| Q33715019 | Screening of the DNA mismatch repair genes MLH1, MSH2 and MSH6 in a Greek cohort of Lynch syndrome suspected families |
| Q61118451 | Shared heritability and functional enrichment across six solid cancers |
| Q64004349 | Shared heritability and functional enrichment across six solid cancers |
| Q49817640 | The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. |
| Q93006972 | The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases |
| Q37596828 | The fate of BRCA1-related germline mutations in triple-negative breast tumors |
| Q92832186 | The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries |
| Q62937864 | Thermal denaturation of the BRCT tandem repeat region of human tumour suppressor gene product BRCA1 |
| Q62937858 | Thermal unfolding of human BRCA1 BRCT-domain variants |
| Q62937853 | Thermodynamic study of the BRCT domain of BARD1 and its interaction with the -pSER-X-X-Phe- motif-containing BRIP1 peptide |
| Q44525487 | Three regions of erythrocyte band 3 protein are phosphorylated on tyrosines: characterization of the phosphorylation sites by solid phase sequencing combined with capillary electrophoresis |
| Q89961489 | Transcriptome-wide association study of breast cancer risk by estrogen-receptor status |
| Q58797082 | Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing |
| Q37414133 | rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk |
Search more.